CHICAGO (Ivanhoe Newswire/WTVM) - Every 70 seconds, someone in the U.S. develops Alzheimer's disease. There is no cure, but there is new hope.
The greatest minds in Alzheimer's research will be in Copenhagen, Denmark July 12-17 discussing the latest breakthroughs and developments in this disease.
A trial, known as "SNIFF" is testing a new insulin nasal spray that could change the way we treat Alzheimer's.
Insulin plays a vital role in managing your body's blood sugar. Neelum Aggarwal, MD, Cognitive Neurologist at Rush University Medical Center says it also plays a key role in brain function.
"If you have Alzheimer's disease, you see specific areas of the brain that are not utilizing the sugar the way they should. That has to do with the insulin receptors." Dr. Aggarwal says, "These areas of the brain now are not working."
That insulin resistance impacts memory and the spray will deliver insulin directly to the brain where changes can take place.
"So if we learn how to modulate the sugar issue and learn how sugar interacts with the brain for brain function, then we have a chance of slowing down the rates of dementia which is our ultimate goal." Aggarwal says.
In a smaller trial, the spray was shown to improve memory and preserve cognitive function in the early stages of Alzheimer's.
The SNIFF study is actively recruiting patients across the country in 29 centers. Qualified patients are non-diabetic and have been diagnosed with mild cognitive impairment or are in the early stages of Alzheimer's disease.